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Summary
Background Tamoxifen and raloxifene reduce the risk of breast cancer in women at elevated risk of disease, but the 
duration of the eﬀ ect is unknown. We assessed the eﬀ ectiveness of selective oestrogen receptor modulators (SERMs) 
on breast cancer incidence.
Methods We did a meta-analysis with individual participant data from nine prevention trials comparing four selective 
oestrogen receptor modulators (SERMs; tamoxifen, raloxifene, arzoxifene, and lasofoxifene) with placebo, or in one 
study with tamoxifen. Our primary endpoint was incidence of all breast cancer (including ductal carcinoma in situ) 
during a 10 year follow-up period. Analysis was by intention to treat.
Results We analysed data for 83 399 women with 306 617 women-years of follow-up. Median follow-up was 
65 months (IQR 54–93). Overall, we noted a 38% reduction (hazard ratio [HR] 0·62, 95% CI 0·56–0·69) in breast 
cancer incidence, and 42 women would need to be treated to prevent one breast cancer event in the ﬁ rst 10 years of 
follow-up. The reduction was larger in the ﬁ rst 5 years of follow-up than in years 5–10 (42%, HR 0·58, 0·51–0·66; 
p<0·0001 vs 25%, 0·75, 0·61–0·93; p=0·007), but we noted no heterogeneity between time periods.  Thromboembolic 
events were signiﬁ cantly increased with all SERMs (odds ratio 1·73, 95% CI 1·47–2·05; p<0·0001). We recorded a 
signiﬁ cant reduction of 34% in vertebral fractures (0·66, 0·59–0·73), but only a small eﬀ ect for non-vertebral 
fractures (0·93, 0·87–0·99).
Interpretation For all SERMs, incidence of invasive oestrogen (ER)-positive breast cancer was reduced both during 
treatment and for at least 5 years after completion. Similar to other preventive interventions, careful consideration of 
risks and beneﬁ ts is needed to identify women who are most likely to beneﬁ t from these drugs.
Funding Cancer Research UK.
Introduction
Large reductions in contralateral tumours shown in 
adjuvant trials with tamoxifen suggest that this drug 
could prevent breast cancer.1,2 Studies of other selective 
oestrogen receptor modulators (SERMs) in trials 
designed to prevent fractures in women with osteo-
porosis have also suggested a preventive eﬀ ect on breast 
cancer. Although SERMs have diﬀ erent chemical 
structures, which can aﬀ ect their speciﬁ c activities, 
they all work by binding to the oestrogen receptor 
and inhibiting the stimulus for cell division. A compre-
hensive review of the mechanisms of action of SERMs 
has been published.3 An earlier meta-analysis4 sum-
marised the early follow-up results of the tamoxifen and 
raloxifene prevention trials. The results showed that 
tamoxifen signiﬁ cantly reduced the risk of oestrogen 
receptor (ER)-positive breast cancer by 48%, but no eﬀ ect 
was noted for ER-negative tumours. Here, we update 
previous meta-analyses, with additional data for short-
term follow-up of lasofoxifene and arzoxifene, to assess 
the eﬀ ect of SERMs on breast cancer incidence.
Methods
Study selection
We searched PubMed with the keywords breast cancer, 
prevention, selective oestrogen receptor modulator (or 
SERM), and chemoprevention. Table 1 provides details of 
the included breast cancer prevention trials. We identiﬁ ed 
nine randomised trials that compared SERMs with placebo 
or another drug in women without breast cancer, and had 
at least 2 years of follow-up. Four trials5,7,9,11 assessed 20 mg 
per day tamoxifen versus placebo for at least 5 years in 
healthy women who were mostly at increased risk of breast 
cancer. Two trials13,14 investigated raloxifene versus pla cebo 
in postmenopausal women who had either osteo porosis, 
or had risk factors for or established coronary heart 
disease.15 A third trial16 compared raloxifene to tamoxifen 
in women at increased risk of developing breast cancer. 
One trial18 compared lasofoxifene at two diﬀ erent doses 
with placebo in postmenopausal women with osteoporosis. 
Finally, one trial20 compared arzoxifene with placebo in 
post menopausal women with osteoporosis. The trials are 
summarised in table 1.
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Statistical analysis
We obtained individual participant data directly from 
the trial investigators. Comparisons were on an 
intention-to-treat basis. We assessed ﬁ xed-eﬀ ects and 
random-eﬀ ects models. Our primary endpoint was 
incidence of all breast cancer (including ductal 
carcinoma in situ) during 10 years of follow-up. 
Secondary endpoints were incidence in years 0–5 and 
years 5–10, and all invasive ER-positive or ER-negative 
cancers, and ductal carcinoma in situ. Other predeﬁ ned 
secondary endpoints were incidence of other cancers, 
venous thromboembolic events, cardiovascular events, 
fractures, cataract, and all-cause mortality.
For the ﬁ xed-eﬀ ects models, we computed log hazard 
ratios (HRs) and their variance separately for each trial and 
then used the inverse variance-weighted method to 
calculate a ﬁ xed-eﬀ ect estimate of the overall log HR and 
its variance. For indirect comparisons between raloxifene 
and placebo in the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) Study of Tamoxifen and Raloxifene 
(STAR) trial, we calculated the log HR for the intervention 
between raloxifene and placebo by sub tracting the ratio for 
the direct comparison between raloxifene and tamoxifen 
by that for the direct com parison between tamoxifen and 
placebo for the other trials. We computed corresponding 
standard errors in a similar way. We included the STAR 
trial only for the raloxifene eﬀ ects, and results for the 
overall eﬀ ect do not include data from that trial.
We explored random-eﬀ ects models, which account 
for variability between trials, and assessed trial hetero-
geneity with Q statistics and I² estimates.22 Data are 
plotted as the proportion of women with the event as a 
function of follow-up time with Kaplan-Meier methods.23 
To compare outcomes between tamoxifen and raloxifene 
we computed the ratio of HRs for comparisons of each 
drug with placebo, then added the direct comparison 
from the STAR trial as a separate stratum to obtain a 
summary hazard ratio. For analysis we used STATA 
(version 11.2) with the meta command. Results are 
presented as HRs with 95% CIs and two-sided p-values.
Role of the funding source
Neither Cancer Research UK nor the funding sources 
for the individual studies had a role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author and IS 
had full access to all the data in the study, and all 
authors had access to analyses. All authors read and 
approved the ﬁ nal decision to submit for publication.
N Recruitment 
period
Treatment groups and daily dose Treatment 
duration (years)
Entry criteria Present status Median follow-up 
(months)
Marsden5,6 2471 1986–96 Placebo (1233)
Tamoxifen 20 mg (1238)
5–8 High risk, family history Blinded, further 
follow-up
171·6 (153·9–184·0)
IBIS-I7,8 7109 1992–2001 Placebo (3566)
Tamoxifen 20 mg (3573)
5 Greater than two times relative risk Blinded, further 
follow-up
96 (80·1–117·1)
NSABP-P-19,10 13 205 1992–97 Placebo (6707)
Tamoxifen 20 mg (6681)
5 >1·6% 5 year risk Unblinded, no 
follow-up
57·6 (35·4–64·9)
Italian11,12 5408 1992–97 Placebo (2708)
Tamoxifen 20 mg (2700)
5 Normal risk, women with 
hysterectomy
Unblinded, 
further follow-up
139·6 (122·0–146·1)
MORE13/CORE14* 7705/6511 1994–98/ 
1998–2002
Placebo (2576) Raloxifene 60 mg (2557)/ 
Placebo (2576) Raloxifene 120 mg (2572)
4/8 Normal risk, postmenopausal 
women with osteoporosis
Unblinded, no 
follow-up
71·3 (47·1–95·4)
RUTH15 10 101 1998–2000 Placebo (5057)
Raloxifene 60 mg (5044)
5 Normal risk, postmenopausal women 
with established or risk of CHD
Unblinded, no 
follow-up
66·7 (60·1–72·3)
STAR16,17 19 490 1999–2004 Raloxifene 60 mg (9875)
Tamoxifen 20 mg (9872)
5 >1·6% 5 year risk, postmenopausal 
women
Unblinded, no 
follow-up
81 (60·8–96.6)
PEARL18,19 8856 2001–07 Placebo (2852)
Lasofoxifene 0·50 mg (2852)
Lasofoxifene 0·25 mg (2852)
5 Normal risk, postmenopausal 
women with osteoporosis
Blinded, no 
follow-up
59·6 (58·8–60·1)
GENERATIONS20,21 9354 2004–09 Placebo (4678)
Arzoxifene 20 mg (4676)
4 Normal risk, postmenopausal with 
low BMD or osteoporosis
Unblinded, no 
follow-up
54·3 (28·3–56·1)
Data in parenthesis are number of randomised participants. CHD=coronary heart disease. BMD=bone mineral density. *The CORE trial was done in a subset of women originally enrolled in the MORE trial.
Table 1: Details of breast cancer prevention trials 
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Figure 1: Cumulative incidence for all breast cancer (including ductal carcinoma in situ) and all ER-positive 
invasive cancers in years 0–10 according to treatment allocation
SERM=selective oestrogen receptor modulator. ER=oestrogen receptor.
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Results
We included nine trials with 83 399 participants and 
306 617 women-years of follow-up (table 1). Median follow-
up was 65 months (IQR 54–93). Figure 1 shows Kaplan-
Meier curves for all breast cancers and invasive ER-positive 
breast cancer for all trials except the STAR trial. Annual 
rates of breast cancer incidence varied substantially 
between trials (table 2), probably because of diﬀ erent entry 
criteria. The overall reduction in all breast cancer 
(including ductal carcinoma in situ) was 38% (p<0·0001; 
table 2), with an estimated 10 year cumulative incidence of 
6·3% in the control groups and 4·2% in the SERM groups. 
We noted the reduction in both years 0–5 of follow-up 
(42%, p<0·0001) and years 5–10 (25%, p=0·007; table 2 and 
ﬁ gure 2). Despite the smaller eﬀ ect in years 5–10, there 
was no evidence of heterogeneity between trials (p=0·3). 
Random-eﬀ ects models produced similar HRs to those for 
the ﬁ xed-eﬀ ects models, but larger 95% CIs (table 2).
Overall, the frequency of invasive ER-positive cancer 
was reduced from 4·0% to 2·1% (p<0·0001; table 2). This 
reduction was apparent in years 0–5 (p<0·0001) and in 
years 5–10 (p<0·0001; table 2 and ﬁ gure 2). The number 
needed to treat to prevent one diagnosis of breast cancer 
in the ﬁ rst 10 years was 42; when restricted to invasive ER-
positive breast cancer the number was 53. Although all 
Overall* Annual 
rates per 
1000†
HR (95% CI) ER-positive 
invasive
HR (95% CI) ER-negative 
invasive
HR (95% CI) DCIS HR (95% CI)
Tamoxifen trials
Marsden 96 vs 114 6·4 0·87 (0·63-1·21) 51 vs 83 0·66 (0·44-0·99) 25 vs 17 1·66 (0·81-3·40) 14 vs 9 1·40 (0·44-4·40)
IBIS I 143 vs 198 6·7 0·72 (0·58-0·90) 88 vs 131 0·69 (0·52-0·90) 36 vs 38 0·97 (0·62-1·54) 16 vs 27 0·52 (0·27-0·99)
NSABP-P-1 130 vs 248 6·1 0·52 (0·42-0·64) 44 vs 134 0·33 (0·23-0·46) 39 vs 31 1·26 (0·78-2·02) 38 vs 70 0·54 (0·36-0·80)
Italian 62 vs 74 4·2 0·83 (0·58-1·19) 36 vs 48 0·73 (0·45-1·17) 16 vs 17 0·87 (0·43-1·79) 9 vs 6 1·80 (0·60-5·38)
Total (0–10 years) 431 vs 634 ·· 0·67 (0·59-0·76) 219 vs 396 0·56 (0·47-0·67) 116 vs 103 1·13 (0·86-1·49) 77 vs 112 0·72 (0·57-0·92)
Total (0–5 years) 256 vs 409 ·· 0·62 (0·53-0·73) 121 vs 235 0·51 (0·41-0·64) 78 vs 76 1·03 (0·75-1·41) 47 vs 83 0·56 (0·39-0·81)
Total (5–10 years) 175 vs 225 ·· 0·78 (0·62-0·97) 98 vs 161 0·63 (0·47-0·83) 38 vs 27 1·55 (0·88-2·72) 30 vs 29 0·87 (0·49-1·57)
Raloxifene trials
MORE/CORE 57 vs 65 4·2 0·42 (0·29-0·60) 22 vs 44 0·24 (0·15-0·40) 15 vs 7 1·06 (0·43-2·59) 13 vs 7 0·91 (0·36-2·28)
RUTH 52 vs 76 4·2 0·67 (0·47-0·96) 25 vs 55 0·45 (0·28-0·72) 13 vs 9 1·44 (0·61-3·63) 11 vs 5 2·17 (0·75-6·25)
STAR‡ (tamoxifen vs raloxifene) 358 vs 447 5·9 0·81 (0·70-0·93) 182 vs 221 0·83 (0·69-1·02) 60 vs 70 0·79 (0·56-1·11) 111 vs 137 0·82 (0·64-1·05)
Total (0–10 years) 467 vs 588 ·· 0·66 (0·55-0·80) 229 vs 320 0·44 (0·34-0·58) 88 vs 93 1·37 (0·96-1·95) 135 vs 149 1·07 (0·68-1·68)
Total (0–5 years) 327 vs 421 ·· 0·63 (0·51-0·79) 168 vs 224 0·40 (0·29-0·56) 62 vs 71 1·27 (0·83-1·95) 86 vs 108 1·08 (0·60-1·96)
Total (5–10 years) 140 vs 167 ·· 0·84 (0·51-1·27) 61 vs 96 0·72 (0·49-1·06) 26 vs 22 1·70 (0·84-3·47) 49 vs 41 0·88 (0·45-1·74)
PEARL
0·25 mg 20 vs 24 2·0 0·82 (0·45-1·49) 9 vs 18 0·49 (0·22-1·10) 7 vs 2 2·83 (0·57-14·02) 4 vs 4 0·99 (0·25-3·99)
0·5 mg 5 vs 24 2·0 0·21 (0·08-0·55) 3 vs 18 0·17 (0·05-0·56) 0 vs 2 ·· 3 vs 4 0·50 (0·09-2·73)
GENERATIONS 22 vs 53 3·2 0·42 (0·25-0·68) 9 vs 30 0·30 (0·14-0·63) 10 vs 10 1·01 (0·42-2·41) 3 vs 10 0·30 (0·08-1·09)
All trials (ﬁ xed eﬀ ect; random eﬀ ect)§
Total (0–10 years) 587 vs 852 4·7 0·62 (0·56-0·69); 
0·61 (0·49-0·75)
287 vs 543 0·49 (0·42-0·57); 
0·44 (0·33-0·60)
160 vs 131 1·14 (0·90-1·45) 
1·14 (0·90-1·45)
110 vs 138 0·69 (0·53-0·90); 
0·79 (0·53-1·19)
Total (0–5 years) 376 vs 594 4·6 0·58 (0·51-0·66); 
0·58 (0·47-0·73)
174 vs 360 0·45 (0·38-0·54); 
0·42 (0·29-0·61)
111 vs 90 1·05 (0·80-1·39); 
1·05 (0·80-1·39)
73 vs 107 0·66 (0·48-0·90); 
0·73 (0·47-1·14)
Total (5–10 years) 211 vs 258 4·9 0·75 (0·61-0·93); 
0·75 (0·59-0·94)
113 vs 183 0·58 (0·45-0·76); 
0·58 (0·45-0·76)
49 vs 32 1·66 (0·98-2·81) 
1·66 (0·98-2·81)
37 vs 31 0·94 (0·53-1·66); 
0·94 (0·53-1·66)
HR=hazard ratio. ER=oestrogen receptor. DCIS=ductal carcinoma in situ. Data are for selective oestrogen receptor modulator versus vs placebo, unless otherwise indicated *All cancers (including DCIS) and those 
with unknown receptor status. †In control group. ‡STAR data not included for overall eﬀ ect. §STAR data not excluded for overall eﬀ ect.
Table 2: Breast cancer incidence in the chemoprevention trials
0–5 years
All breast cancer
Invasive ER-positive
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HR (95% CI)
0·58 (0·51–0·66)
0·45 (0·38–0·54)
5–10 years
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Invasive ER-positive
HR (95% CI)
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Figure 2: Annual hazard rate for all breast cancers (including ductal carcinoma in situ) and invasive ER-positive 
breast cancer in years 0–10 with ﬁ xed-eﬀ ects models23
ER=oestrogen receptor. SERM=selective oestrogen receptor modulator. 
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trials showed a reduction in breast cancer incidence, we 
noted substantial heterogeneity between trials in the size 
of the eﬀ ect for all breast cancers and invasive ER-positive 
cancers (ﬁ gure 3), and for invasive cancers. We noted a 
non-signiﬁ cant increase in invasive ER-negative breast 
can cers (p=0·3; table 2). The incidence of ductal carcinoma 
in situ was signiﬁ cantly reduced overall by 31% (p=0·006; 
table 2). We noted a 38% reduction in incidence in the 
tamoxifen trials, but no eﬀ ect for raloxifene; however, 
signiﬁ cant heterogeneity was shown between trials. Little 
infor mation was available for the eﬀ ect of lasofoxifene and 
arzoxifene on ductal carcinoma in situ.
For tamoxifen trials, we noted a signiﬁ cant reduction of 
33% (p<0·0001) in all breast cancers compared with 
placebo (table 2 and ﬁ gure 3). This reduction was mainly 
due to a large eﬀ ect on ER-positive invasive breast cancer, 
for which we noted a reduction of 44% (p<0·0001; table 2) 
and a signiﬁ cant reduction in DCIS (p=0·009; table 2), but 
a non-signiﬁ cant increase in ER-negative tumours was 
recorded (p=0·4; table 2). Sig niﬁ cant heterogeneity was 
shown between trials for all breast cancers (p=0·02) and 
invasive ER-positive breast cancers (p=0·03). For raloxifene 
trials, we noted a signiﬁ cant reduction in incidence of all 
breast cancer (p<0·0001; table 2) due to a reduction in 
invasive ER-positive breast cancers, with a non-signiﬁ cant 
increase in the incidence of invasive ER-negative breast 
cancers and no eﬀ ect on DCIS (table 2 and ﬁ gure 3). When 
we compared raloxifene with tamoxifen, the only sig-
niﬁ cant diﬀ erence in eﬀ ect size was a greater eﬀ ect for 
tamoxifen in DCIS (HR 0·78, 95% CI 0·61–0·99; p=0·04).
The PEARL and GENERATIONS trials had follow-up 
results for only years 0–5. All breast cancers (p<0·0001) 
and ER-positive cancers (p<0·0001; table 2) were 
signiﬁ cantly reduced with 0·5 mg per day of lasofoxifene 
compared with placebo, whereas only a small eﬀ ect was 
noted for women receiving 0·25 mg per day (table 2 and 
ﬁ gure 3). We noted a non-signiﬁ cant increase in inci-
dence for invasive ER-negative breast cancer (HR 1·43, 
95% CI 0·43–1·66) and a non-signiﬁ cant decrease for 
ductal carcinoma in situ (0·76, 0·26–2·21; p=0·6) when 
both treatment groups were combined. Arzoxifene 
reduced all breast cancer occurrence by 58% (p=0·001; 
table 2). Invasive ER-positive breast cancers were reduced 
by 70% (p=0·002), whereas no eﬀ ect was noted for 
invasive ER-negative breast cancers (p=0·9; table 2 and 
ﬁ gure 3). Incidence of ductal carci noma in situ was 
reduced, but not substantially so (p=0·07; table 2). 
No trial was designed to look at mortality as an endpoint, 
and no eﬀ ect of any SERM was reported for all causes of 
death (table 2). Data for cause-speciﬁ c mortality was not 
available for most of the non-tamoxifen trials. No eﬀ ect 
on breast cancer death was reported in the tamoxifen 
trials on the basis of a total of 59 deaths (table 2).
Table 3 and ﬁ gure 4 present major events for each trial. 
Overall, women receiving a SERM had a higher rate of 
endometrial cancer than did those given placebo 
(p=0·007; table 3) but the increase was conﬁ ned to the 
ﬁ rst 5 years of follow-up (HR 1·64, 1·14–2·36; p=0·007) 
and was not apparent during years 5–10, the period after 
treatment (0·85, 0·38–1·89; p=0·7). The eﬀ ect seemed to 
be limited to the tamoxifen trials (2·18, 1·39–3·42; 
p=0·001) and no increase was shown in the raloxifene 
trials (1·09, 0·74–1·62; p=0·7). Too few endometrial 
cancers were reported with lasofoxifene to make a 
Tamoxifen trials
Marsden
IBIS-I
NSABP-P1
Italian
Raloxifene trials
MORE/CORE
RUTH
STAR*†
Lasofoxifene trial
PEARL 0·25 mg
PEARL 0·5 mg‡
Arzofoxifene trial
GENERATIONS
Combined†
DCISAll breast cancer ER–positive invasive breast cancer ER–negative invasive breast cancer
Hazard ratio p=0·002
10·50·20·1
Hazard ratio p<0·001
10·50·20·1 2
Hazard ratio p=0·9
1 20·5 5
Hazard ratio p=0·09
10·50·20·1 2 5 10
Figure 3: All breast cancers, invasive breast cancer, and DCIS in years 0–10
ER=oestrogen receptor. DCIS=ductal carcinoma in situ. *Adjusted by overall tamoxifen eﬀ ect to give raloxifene versus placebo comparisons. †STAR data not included 
in comparisons. ‡Data for ER-invasive cancer are pooled.
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meaningful interpretation, but an increase of 2·3 times 
was noted with arzoxifene (2·26, 0·70–7·32; p=0·2).
1586 cancers other than breast or endometrial cancer 
were reported. These cancers were evenly distributed 
between the treatment groups (p=0·8; table 3) and no 
heterogeneity between trials was noted (p=0·8). A non-
signiﬁ cant reduction was noted for ovarian cancer 
(OR 0·84, 95% CI 0·60–1·19; p=0·3) and there was no 
eﬀ ect on colorectal cancer (1·04, 0·85–1·27; p=0·7). 
Venous thromboembolic events were signiﬁ cantly in-
creased overall (p<0·0001; table 3 and ﬁ gure 4). We noted 
similar ORs in the tamoxifen and raloxifene trials 
(1·60, 1·21–2·12; p=0·001 vs 1·45, 1·18–1·76; p<0·0001; 
ﬁ gure 4), but the rate was higher for arzoxifene (2·55, 
1·45–4·47; p=0·001) and lasofoxifene (ORpooled 2·38, 
1·43–3·97; p=0·001), and no signiﬁ cant heterogeneity 
was noted between trials. Overall, no eﬀ ect of SERMs 
was noted for myocardial infarction, stroke, or transient 
ischaemic attacks, and there was no evidence for hetero-
geneity, except for a signiﬁ cant reduction in strokes for 
lasofoxifene (OR 0·67, 0·48–0·92; p=0·01; ﬁ gure 4).
All fractures were signiﬁ cantly reduced by SERMs 
(p<0·001; table 3 and ﬁ gure 4). This reduction was 
mainly driven by a decrease in the PEARL trial (0·73, 
0·66–0·81; p<0·0001), but decreases were also noted in 
the raloxifene and GENERATIONS trials (ﬁ gure 4). By 
contrast, no eﬀ ect was seen with tamoxifen (0·92, 
0·83–1·02). We noted a greater eﬀ ect when we restricted 
ﬁ ndings to those for vertebral fractures; however, such 
fractures were rare in the tamoxifen and STAR trials, and 
not recorded in the Italian trial, and only well documented 
in the osteoporosis trials in which follow-up spinal 
radiographs were done (MORE and CORE, PEARL, and 
GENERATIONS trials). When restricted to these trials, 
we noted a 41% reduction in vertebral fractures (0·59, 
0·52–0·67; p<0·0001). We recorded a small eﬀ ect for 
non-vertebral fractures overall (table 3), which seemed to 
be greatly aﬀ ected by the 0·5 mg dose of lasofoxifene 
(OR 0·81, 0·67–0·98; ﬁ gure 4); however, no heterogeneity 
was shown (p=0·8). Overall cataracts were evenly 
distributed between treatment groups (table 3), but a 
small increase was observed with tamoxifen (1·10, 
1·01–1·21; p=0·04).
Discussion
This report is the only comprehensive analysis of all the 
SERM prevention trials, and use of individual participant 
data enabled us to undertake various analyses that were 
not done in the published reports. We provide here a 
substantial update of our previous report,4 which was 
limited to results for short term follow-up and only 
assessed tamoxifen and raloxifene. Our ﬁ ndings clearly 
show that SERMs signiﬁ cantly reduce the risk of all 
breast cancer in high-risk and average-risk women who 
do not have the disease, which is due to a reduction in 
ER-positive invasive breast cancer. No eﬀ ect was noted 
for ER-negative breast cancers, for which new approaches 
are still needed. All SERMs except raloxifene had an 
eﬀ ect on ductal carcinoma in situ.
Beneﬁ ts were noted during the active treatment period, 
but also after treatment was completed. The reduction in 
ER-positive invasive tumours in years 5–10 of follow-up 
was largely restricted to the tamoxifen and raloxifene 
trials. Long-term follow-up is needed to establish the full 
duration of protection for these drugs and to identify 
whether any carryover eﬀ ect will be shown for laso-
foxifene and arzoxifene. Whether the non-signiﬁ cant 
increase in ER-negative invasive tumours is a chance 
ﬁ nding or biologically relevant is unclear. For example, 
some of these tumours could have arisen as ER-positive 
Endometrial 
cancer
All other 
cancer*
Any death Breast 
cancer 
death
Venous 
thrombolic 
events†
Cardio-
vascular 
events‡
All fractures Non-vertebral 
fractures
Vertebral 
fractures
Cataracts
Marsden 12 vs 5 55 vs 60 54 vs 54 12 vs 9 ·· ·· ·· ·· ·· ··
IBIS-I 19 vs 11 110 vs 113 65 vs 55 10 vs 12 65 vs 43 40 vs 38 229 vs 252 221 vs 244 8 vs 8 76 vs 70
NSABP-P-1 36 vs 15 101 vs 103 59 vs 71 4 vs 6 55 vs 29 90 vs 82 502 vs 539 480 vs 509 22 vs 30 578 vs 513
Italian ·· 106 vs 91 36 vs 38 2 vs 2 11 vs 10 14 vs 10 ·· ·· ·· ··
MORE/CORE 6 vs 8 112 vs 132 81 vs 84 ·· 47 vs 25 82 vs 78 353 vs 450 214 vs 225 139 vs 225 275 vs 280
RUTH 21 vs 17 204 vs 203 548 vs 585 2 vs 0 106 vs 73 487 vs 481 529 vs 591 470 vs. 499 59 vs 92 570 vs 561
STAR§ (raloxifene vs tamoxifen) 37 vs 65 354 vs 323 202 vs 236 4 vs 11 154 vs 202 233 vs 220 1272 vs 1364 1195 vs 1299 65 vs 77 603 vs 739
PEARL (0·5 mg vs 0·25 mg vs 
placebo)
2 vs 2
vs 3
25 vs 20 
vs 22
92 vs 73 
vs 65
·· 48 vs 37 
vs 18
47 vs 54 
vs 76
359 vs 422 
vs 508
203 vs 233 
vs 246
156 vs 189 
vs 262
320 vs 317 
vs 330
GENERATIONS 9 vs 4 74 vs 75 103 vs 98 ·· 43 vs 17 71 vs 64 426 vs 508 316 vs 327 110 vs 181 382 vs 400
All events 105 vs 63 787 vs 799 1038 vs 1050 30 vs 29 375 vs 215 831 vs 829 2398 vs 2848 1904 vs 2050 494 vs 798 2201 vs 2154
HR or OR (95% CI) HR 1·56 
(1·13–2·14)
HR 0·98 
(0·89–1·08)
HR 0·98 
(0·90–1·06)
HR 1·03 
(0·55–1·92)
OR 1·73 
(1·47–2·05)
OR 0·99 
(0·91–1·09)
OR 0·85 
(0·80–0·89)
OR 0·93 
(0·87–0·99)
OR 0·66 
(0·59–0·73)
OR 1·01 
(0·95–1·06)
Data are number of patients for selective oestrogen receptor modulator versus vs placebo, unless otherwise indicated. HR=hazard ratio. OR=odds ratio *Excluding endometrial cancer. †Including deep vein thrombosis, 
pulmonary embolism, retinal thrombosis; excluding superﬁ cial thrombosis. ‡Including myocardial infarction, cerebrovascular accident, and transient ischaemic accident. §STAR data not included for overall eﬀ ect.
Table 3: Major non-breast cancer events in the prevention trials
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cancers in the absence of a SERM, and treatment might 
have delayed their emergence, but they developed 
endocrine resistance, eventually escaped control, and 
emerged as ER-negative tumours. No evidence that 
SERMs had an eﬀ ect on breast-cancer-speciﬁ c or overall 
mortality was noted. In view of the continuing eﬀ ect on 
breast cancer incidence in years 5–10, further follow-up 
will be needed to establish whether there is a reduction 
in deaths from breast cancer. All drugs increased venous 
thromboembolic events, but only tamoxifen showed a 
clear increase in endometrial cancers. No other type of 
cancer seemed to be aﬀ ected by SERM use. Despite a 
10–20% reduction in LDL cholesterol with SERMs, no 
reduction in cardiovascular disease was noted.
The large amount of extended follow-up available for 
this analysis has provided a clear overview of the beneﬁ ts 
and harms of these drugs. The higher (0·5 mg per day) 
dose of lasofoxifene is a promising candidate for pre-
vention, because it not only had a large eﬀ ect on breast 
cancer incidence but also showed beneﬁ ts for stroke, 
cardiac events, and vertebral fractures, with no increase in 
endometrial cancer. Further studies on this compound 
Tamoxifen trials
Marsden
IBIS-I
NSABP-P1
Italian
Raloxifene trials
MORE/CORE
RUTH
STAR*†
Lasofoxifene trial
PEARL‡
Arzofoxifene trial
GENERATIONS
Combined†
All other cardiac or
cerebrovascular events
Endometrial cancer All other cancer Venous thromboembolic 
events
Hazard ratio p=0·2
10·50·2 52 10
Hazard ratio p=0·5
210·50·2 5
Hazard ratio p=0·4
1 20·5 5
Hazard ratio p=0·6
10·50·2 2 5
A
Tamoxifen trials
 IBIS-I
 NSABP-P1
Raloxifene trials
 MORE/CORE
 RUTH
 STAR*†
Lasofoxifene trial
 PEARL 0·25 mg
 PEARL 0·5 mg
Arzofoxifene trial
 GENERATIONS
Combined†
Non-vertebral fracturesAll fractures Vertebral fractures
Hazard ratio p=0·01
1
Odds ratio
0·5
Hazard ratio p=0·3
1
Odds ratio Odds ratio
0·5 2 10·5 2
Hazard ratio p=0·8
B
Figure 4: Forest plots for adverse events
(A) Endometrial cancer, other cancer, venous thromboembolic events, and cardiac or stroke events. (B) All fractures, vertebral fractures and non-vertebral fractures. 
*Adjusted by overall tamoxifen eﬀ ect to give raloxifene versus placebo comparisons. †STAR data not included in comparisons. ‡Data are pooled.
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should be a priority for prevention research. Further more, 
the direct comparison of tamoxifen with raloxifene in the 
STAR trial has shown that raloxifene is less eﬀ ective than 
tamoxifen, but has fewer side-eﬀ ects. Limitations of our 
analysis are that the GENERATIONS and PEARL trials, 
and one of the raloxifene trials, were done on average-risk 
women with osteoporosis. Longer follow-up is also 
desirable for the lasofoxifene and arzoxifene trials. Only 
tamoxifen has been assessed in premenopausal women, 
in whom it is the only drug with proven eﬀ ectiveness.
New prevention trials with aromatase inhibitors are 
promising, but these drugs are only suitable for 
postmenopausal women. Several adjuvant studies have 
shown an eﬀ ect in new contralateral tumours,24 and one 
trial in the preventive setting has shown a very large eﬀ ect 
on short-term incidence for exemestane.25 Results from 
another prevention trial of anastrozole are awaited,24 and 
a comparison of aromatase inhibitors with SERMs might 
be needed when long-term data for aromatase inhibitors 
are available. The duration of the SERM beneﬁ t on breast 
cancer incidence is unknown, but this analysis conﬁ rms 
that beneﬁ ts last for at least 5 years after treatment 
completion. Tamoxifen-speciﬁ c adverse events (eg, 
thromboembolic events and endo metrial cancer) are 
largely conﬁ ned to the active treatment period and are 
few after treatment has ceased. However, similar to other 
preventive interventions, in cluding oral contraceptives 
and prophylactic cardio vascular medicines, careful 
consideration of potential beneﬁ ts and harms during the 
decision making process is needed to identify women 
most likely to beneﬁ t. Improved beneﬁ t–harm ratios are 
most likely to be achieved by enhanced targeting of 
women at high risk of ER-positive postmenopausal breast 
cancer. As such, use of mammographic breast density26 
and panels of single nucleotide polymorphisms,27 each of 
which individually only identify a modest increase of risk, 
seem to be the most likely new risk factors.
Despite their eﬀ ectiveness, SERMs have not been 
widely accepted as breast cancer preventive drugs by 
high-risk women and their primary care physicians, 
mainly because of concern about toxic eﬀ ects and a 
perceived unfavourable balance between beneﬁ ts and 
harms. Unfortunately, at the present time, none of these 
drugs are being actively marketed for breast cancer 
prevention, and approval by the US Food and Drug 
Administration or any other regulatory authority for this 
indication will probably not be sought for lasofoxifene or 
arzoxifene. Our longer term assessment shows that the 
beneﬁ t–harm balance is now more favourable than that 
calculated for short term follow-up, and, in view of this 
new evidence, assessment of these drugs, especially 
lasofoxifene, should be continued.
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